Orchid Pharma Q1 FY26 Earnings Results

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. Presenting below are its Q1 FY26 earnings results.

 

Q1 FY26 Earnings Results

• Total Revenue: ₹172.93 crores, down 27.18% QoQ from ₹237.48 crores in Q4 FY25, down 29.25% YoY from ₹244.41 crores in Q1 FY25.

• Operating Profit: ₹14.71 crores, up 88.11% QoQ from ₹7.82 crores, up 32.88% YoY.

• PBDT (Profit Before Depreciation and Tax): ₹8.65 crores, down 2.04% QoQ and up 4.34% YoY.

• Profit Before Tax (PBT): ₹14.91 crores, down 32.99% QoQ, down 48.94% YoY.

• Net Profit (PAT): ₹14.91 crores, down 33.11% QoQ, down 48.20% YoY.

• Basic EPS: ₹2.94 for Q1 FY26.

• Expenses: ₹171 crores, down 23.6% YoY.

 

Management Commentary & Strategic Overview

• Management cited subdued demand and pricing pressure in the global generic and specialty API markets impacting Q1 revenue.

• Focus on operational efficiencies and cost controls helped improve margins despite revenue decline.

• Strategic emphasis on developing niche specialty APIs and vertically integrated formulations for better profitability.

• Management remains optimistic on recovery from H2 FY26 supported by new product launches and improving market dynamics.

• Appointment of Independent Director Tanu Singla strengthens governance.

 

 

Q4 FY25 Earnings Results

• Total Revenue: ₹237.48 crores.

• Operating Profit: ₹7.82 crores.

• Profit Before Tax (PBT): ₹22.25 crores.

• Net Profit (PAT): ₹22.29 crores.

• Basic EPS: ₹4.39

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.